Basic Information
Ebglyss
Regulatory Information
EMEA/H/C/005894
Authorised
November 16, 2023
September 14, 2023
3
April 10, 2025
Company Information
Spain
Ronda General Mitre, 151 ES-08022 Barcelona
Almirall, LLC
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Overview Summary
Ebglyss is a medicine used to treat moderate to severe atopic dermatitis (also known as atopic eczema, when the skin is itchy, red and dry). It is used in adults and children aged 12 years and over weighing at least 40 kg. It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient. Ebglyss contains the active substance lebrikizumab.